MDxHealth names Michael Holder to board, CFO Ron Kalfus to depart

Published 03/07/2025, 18:06
MDxHealth names Michael Holder to board, CFO Ron Kalfus to depart

IRVINE, California - MDxHealth SA (NASDAQ:MDXH), a precision diagnostics company with a market capitalization of $109 million, has appointed Michael Holder to its Board of Directors as Chair of the Audit Committee, while announcing the resignation of Chief Financial Officer Ron Kalfus, according to a company press release issued Thursday. According to InvestingPro analysis, the company operates with a moderate debt level while maintaining strong revenue growth of 25% in the last twelve months.

Holder, who brings over 30 years of experience including nine board positions and roles as CEO and CFO across various healthcare companies, will replace Regine Slagmulder, whose term ended in May. He currently serves as Chair of the Audit Committee at Cytek Biosciences Inc. (NASDAQ:CTKB) and holds an MBA from the Wharton School.

Kalfus will continue in his role until July 30, after which Scott McMahan, Vice President of Finance and Accounting, will assume CFO responsibilities on an interim basis.

"Michael’s remarkable 30-plus years of diverse experience across the biotech, medtech, and pharma industries, combined with his deep expertise in corporate strategy, fundraising, and his financial acumen, will be invaluable," said Michael K. McGarrity, CEO of MDxHealth.

Board Chair Koen Hoffman thanked both Slagmulder for her service as Audit Committee Chair and Kalfus for his contributions as CFO.

MDxHealth, which specializes in precision diagnostics for urologic cancers and diseases, maintains U.S. headquarters and laboratory operations in Irvine, California, with additional facilities in Plano, Texas, and European headquarters in Herstal, Belgium. The company’s stock currently trades below its InvestingPro Fair Value, presenting a potential opportunity for investors seeking exposure to the precision diagnostics sector.

In other recent news, MDxHealth SA has announced the rescheduling of its Extraordinary General Meeting (EGM) to June 27, 2025, in Ghent, Belgium. This decision follows the company’s inability to meet the required attendance quorum at the initial meeting. Despite this, the Ordinary Annual General Meeting (AGM) held on May 28, 2025, successfully approved all proposed resolutions, even in the absence of the quorum. The upcoming EGM will take place at 3:00 p.m. at the offices of the notary public Stijn Raes and will not require an attendance quorum to proceed. The agenda will cover items that were not addressed previously due to the quorum issues. MDxHealth SA has made the relevant documents for the EGM available as exhibits in an SEC filing. This development is based on a press release statement from the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.